openPR Logo
Press release

Lawsuit filed for Investors in shares of Natera, Inc. (NASDAQ: NTRA)

05-04-2022 01:43 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Natera, Inc. (NASDAQ: NTRA) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Natera, Inc. (NASDAQ: NTRA) shares over alleged securities laws violations.

An investor, who purchased shares of Natera, Inc. (NASDAQ: NTRA), filed a lawsuit over alleged Securities Laws violations by Natera, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Natera, Inc. (NASDAQ: NTRA) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2022. NASDAQ: NTRA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, alleging that positive results on tests are incorrect about 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy."

On January 14, 2022, the Campaign for Accountability-a nonprofit watchdog group-filed a complaint with the U.S. Securities and Exchange Commission requesting an investigation as to whether Natera, Inc. repeatedly claimed - in marketing materials and earnings calls - that its tests are much more reliable than it appears they really are.

On March 9, 2022, Hindenburg Research issued an investigative report alleging, among other things, that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."

On March 14, 2022, a jury found that Natera had intentionally and willfully misled the public by utilizing false advertisements to market Prospera in violation of federal and state laws. Among other things, the jury found that Natera's marketing falsely claimed that Prospera was more accurate than the competing kidney transplant testing offered by CareDx, Inc. Ultimately, the jury awarded CareDx, Inc. $44.9 million in monetary damages.

On April 19, 2022, the United States Food and Drug Administration (FDA) issued a safety communication "to educate patients and health care providers and to help reduce the inappropriate use of [NIPTs]." The FDA cautioned that statements about NIPTs' reliability and accuracy "may not be supported with sound scientific evidence" and revealed the existence of "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy." The FDA suggested that patients discuss benefits and risks with a healthcare provider before deciding to undergo NIPT or making any pregnancy-related decisions on the basis of NIPT results. In addition, the FDA advised health care providers that they should not rely on NIPT results alone to diagnose chromosomal abnormalities or disorders.

Shares of Natera, Inc. (NASDAQ: NTRA) declined from $96.80 per share on December 17, 2021, to as low as $33.89 per share on April 28, 2022.

The plaintiff claims that between February 26, 2020, and April 19, 2022, the Defendants misrepresented and/or failed to disclose that Panorama was not reliable and resulted in high rates of false positives, that Prospera did not have superior precision compared to competing tests, that as a result of Defendants' false and misleading claims about Natera's technology, the company was exposed to substantial legal and regulatory risks, that Natera relied upon deceptive sales and billing practices to drive its revenue growth, and that as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.

Those who purchased shares of Natera, Inc. (NASDAQ: NTRA) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Natera, Inc. (NASDAQ: NTRA) here

News-ID: 2616459 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Natera

Liquid Biopsy Market Is Booming So Rapidly | GRAIL, Freenome, Natera
The Global Liquid Biopsy Market Size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 12.4% to reach $16.3 Billion by 2034. The latest study released on the Global Liquid Biopsy Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Liquid Biopsy market study covers significant research data and proofs to be a handy resource document for
Hereditary Testing Market Is Booming Worldwide with Invitae, Illumina, Natera
The Hereditary Testing Market study with 180+ market data Tables, Pie charts & Figures is now released by USD Analytics. The research assessment of the Market is designed to analyze futuristic trends, growth factors, industry opinions, and industry-validated market facts to forecast till 2030. The market Study is segmented by key a region that is accelerating the marketization. This section also provides the scope of different segments and applications that
Noninvasive Prenatal Testing (NIPT) Market | Counsyl, Illuminansyl, Intergrated …
The global noninvasive prenatal testing (nipt) market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the noninvasive prenatal testing (nipt) market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving
Investigation for Long-Term Investors in Natera, Inc. (NASDAQ: NTRA) over potent …
An investigation was announced for current long-term investors in shares of Natera, Inc. (NASDAQ: NTRA) concerning potential breaches of fiduciary duties by certain directors and officers of Natera, Inc. Investors who are current long term investors in Natera, Inc. (NASDAQ: NTRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Investigation announced for Long-Term Investors in Natera, Inc. (NASDAQ: NTRA)
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Natera, Inc. Investors who purchased shares of Natera, Inc. (NASDAQ: NTRA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Natera, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. San Carlos, CA based
Prenatal Genetic Testing Industry 2019-2025 Global Market Share, Segments, Manuf …
This study estimates the factors that are boosting the development of the global Prenatal Genetic Testing market, on the basis of key principles segments such as end-users, application, product, technology, and region are surveyed comprehensively. A thorough examination has been done in this report to bring about the share and position. In the report, a complete analysis of the growth revenue is offered. Get Sample copy @ https://www.orianresearch.com/request-sample/802116 Analysis of Key Manufacturers: • Sequenom